Comparison of Silevimig, a Novel Bispecific Anti-Rabies Monoclonal Antibody, with Human Rabies Immunoglobulin for Post-Exposure Prophylaxis: A Phase III, Randomized, Double-Blind, Non-Inferiority Trial. (academic.oup.com)

Authors: Wang X … Liu X Journal: Clinical Infectious Diseases Published: 2026-09-21 DOI: https://doi.org/10.1093/cid/ciag551